Reporting of adverse events ONLY

Patients should always seek the advice of a doctor or pharmacist in case of adverse events.

If you wish to report an adverse event to ELC Group s.r.o., please find the contact information below:

+420 224 910 672

(from 09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

To contact us about any other issue please call:

+420 22 491 0000or our regional offices.

Hlášení nežádoucích príhod

Pacienti by meli vždy požádat o radu svého lékare nebo lékárníka v prípade výskytu nežádoucích príhod.

Pokud chcete nahlásit nežádoucí príhodu spolecnosti ELC Group s r.o., prosím využijte kontaktních údaju níže:

+420 224 910 672

(09.00-17.30 CET)

+420 226 251 459

(non-stop 24/7)

Pro záležitosti, které se netýkaji farmakovigilance, kontaktujte prosím recepci:

+420 22 491 0000 nebo naše další pobočky.

Formulation development

ELC successfully supports many clients with all aspects of formulation development and CMC services as shown here:
  • Pre-formulation profiling
  • Active Product Ingredient (API) qualification and testing
  • Formula optimisation
  • Process optimisation
  • Analytical method development and validation
  • Quality by Design (QbD) development
  • Stability studies
  • Scale up and technology transfer
  • Method transfer
  • Process validation
13
ongoing formulation development projects

Types of dosage:

Solid Oral Dosage Forms

Tablets

Immediate release
Orally dispersible
Delayed release
Sustained release – Matrix/Diffusion
Multi-particulate – IR/SR/DR
Bi-layered
Tri-layered

Capsules

Hard gelatine capsules
Tablet in capsule

Tablet in capsule

Liquid orals
Dry syrups

Scale up and commercial manufacturing

Pilot batch manufacturing
Exhibit batch manufacturing
Commercial manufacturing